A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Stern, Jerry O ^a   Robinson, Patrick A ^a   Love, James ^a   Lanes, Stephan ^a   Imperiale, Michael S ^a   Mayers, Douglas L ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Antiretroviral therapy; Hepatotoxicity; HIV; Liver enzyme elevations; Nevirapine

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RASH; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; T LYMPHOCYTE;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CLINICAL TRIALS; COHORT STUDIES; HIV INFECTIONS; HUMANS; LIVER; LIVER FAILURE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 0141681334     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00005     Document Type: Conference Paper

References (33)

1. Reisler R, Servoss JC, Sherman KE, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials; ACTG Liver Diseases Focus Group [abstract 43]. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 8-11 2001.
2. Food and Drug Administration (FDA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and the American Association for the Study of Liver Diseases (AASLD). Drug-Induced Liver Disease: A National and Global Problem, White Papers. Available at: http://www.fda.gov/cder/livertox, Chantilly VA, U.S.A., February 12-13 2001.
3. Report of an International Consensus Meeting: Criteria of Drug-induced liver disorders, Council for International Organizations of Medical Sciences. J Hepatol 1990;11:272-276.
4. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31.
5. Savès M, Vandentorrena S, Daucourta V, et al. and the Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA). Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998. AIDS 1999;13:F115-F121.
6. Martinez E, Blanco J, Arnaiz J, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-1268.
7. d'Arminio-Monforte A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001;28:114-123.
8. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventative therapy. JAMA 1999;281:1014-1018.
9. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-217.
10. Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-431.
11. 11. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-189.
12. Dieterich DT, Robinson PA, Stern JO, Hall D, Love J and Carlier H. Analysis of four key clinical trials to assess risk of hepatotoxicity with nevirapine: correlation with hepatitis B and C seropositivity, baseline and emergent liver function tests, and Cd4+ levels [abstract #44]. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8-11, 2001.
13. Johnson S, Baraboutis JG. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000;284:2722-2723.
14. Anon. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR 2001;49:1153-1156.
15. Stern J, Love J, Robinson P, et al. Hepatic safety of nevirapine: results of the Boehringer Ingelheim Viramune® Hepatic Safety Project [abstract LBOr15]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
16. Cali CM, Duh M-S, Ho VT, et al. Hospitalization for hepatic and pancreatic disease among users of antiretroviral therapy in the US [poster 542]. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 8-11, 2001.
17. Purdum AG, Goldberg GA, Wade SW, et al. Nevirapine is not associated with an increased risk of clinically significant hepatitis compared with other antiretroviral medications [abstract 102]. Presented at the HIV DART, Puerto Rico, December 17-21 2000.
18. Dieterich D, Becker S, Fusco J, et al. Low incidence of grade III/IV hepatotoxicity in first HAART observations from 1,237 patients followed for one year [poster 4534]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12 2002.
19. Bartlett J. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor [abstract 19]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections (CROI), Chicago, February 4-8 2001.
20. Sanne I, on behalf of the FTC-302 study investigators and the FTC-302 independent clinical steering committee. Severe liver toxicity in patients receiving two nucleoside analogs and a non-nucleoside reverse transcriptase inhibitor [abstract PL9.3]. Presented at the 5th International Congress on Drug Therapy in HIV infection, Glasgow, October 22-26 2000.
21. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003;4:115-120.
22. Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:340-345.
23. Ena J, Amador C, Pasquau F, et al. Risk and determinants of developing severe hepatic cytolysis during therapy with non-nucleoside analogue reverse transcriptase inhibitor combinations in HIV-infected patients [abstract I-208]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, December 16-19 2001.
24. Puoti M, Patroni A, Pan A, et al. Hepatotoxicity associated with non nucleoside reverse trascriptase inhibitors (NNRT) in 427 adults infected with HIV [p.129]. Presented at the 8th ECCATH, Athens, Greece, October 28-31, 2001.
25. Font C, Guitart R, Soler A, et al. Nevirapine and liver hepatotoxicity: relevance in clinical practice [p.162]. Presented at the 5th International Congress Drug Therapy, Glasgow, Scotland, October 22-26, 2000.
26. Fernandez-Guerrero ML, Becares J, Gorgolas M, Garcia-Delgado R. Nevirapine induced acute hepatitis [presentation 209]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Madrid, Spain, 2001.
27. Sabin CA, Fisher M, Churchill D, et al. Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine. J Acquir Immune Defic Syndr 2001;26:462-465.
28. Moreno A. Nevirapine-associated hepatotoxicity [abstract 1-207]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, December 16-19 2001.
29. Fisher M, Pozniak AL, Churchill DR, et al. The efficacy and safety of nevirapine (NVP) in clinical practice: Experience in over 500 patients in the UK [abstract 32248]. Presented at the 12th World AIDS Conference, Geneva, June 28 1998.
30. Ruiz L, Negredo E, Domingo P, et al., and the Spanish Lipodystrophy Group. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-236.
31. Caldeira L, Cruz J, Aguiar P, et al. Non-nucleoside reverse transcriptase inhibitor (NNRT) hepatotoxicity in HIV-infected patients with and without chronic viral hepatitis [PL12.2]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections (CROI), Portugal, February 2003.
32. deMaat MMR, Mathot RAA, Veldkamp AI, et al. Hepatotoxicity following nevirapine-containing regimens in HIV-1 infected individuals. Pharm Res 2002;46:295-300.
33. Lanes S. Reporting rates of adverse events for antiretroviral medications, 1996-2000. Unpublished data, Boehringer Ingelheim Pharmaceuticals, 2001.